Pharmaceutical manufacturing facility
In March 2018, Aldevron initiated the construction of a good manufacturing practice (GMP) compliant plasmid manufacturing facility in Fargo, North Dakota, US.
Scheduled for completion in the second half of 2018, the new facility is expected to be the world’s biggest plasmid DNA manufacturing facility.
Aldevron is a biotechnology company based in the US. It has made a $30m investment in the new facility, which is expected to double the company’s GMP manufacturing capacity and enable it to meet the growing demand for current good manufacturing practice (cGMP) products.
Aldevron’s new plasmid manufacturing facility will have a total floor space of 70,000ft², including 17,000ft² of modular cleanrooms, which will be used for cGMP production.
The facility will also include ISO 8 and ISO 7 processing suites for cell banking and fermentation, as well as an EU-compliant Grade A product dispensing zone. The fermentation scale of the facility will range from 10l to 300l single-use systems, with provision for expansion to 2,000l in the future.
The product-dispensing and cell-banking suites will feature single-pass airflow, and the production area will feature a unidirectional personnel flow and airlocks. The cleanroom systems at the facility will be designed to provide customers with high-quality manufacturing.
The facility will also be equipped with an emergency generator back-up power, automated alarms and environmental monitoring.
The new facility will provide high-quality plasmid DNA manufacturing services using single-use fermentation (SUF) technology, which minimises the need for costly cleaning validations and reduces the time between GMP production runs.
The plant will produce a variety of plasmid DNA catalogue items, which will be used to carry out research in mammalian cells. It will produce research-grade plasmid DNA, GMP-Source™ plasmid DNA, and GMP plasmid DNA.
The research-grade plasmid DNA is used in research applications in small, mid-size, large and high-throughput production scales, while the GMP-Source™ plasmid DNA is used as a subsidiary or critical raw material for manufacturing protein and viral candidates used in clinical trials.
Aldevron provides a range of customised GMP plasmid DNA services ranging from early research to commercial supply.
US-based cleanroom expert AES Clean Technology was contracted to design and construct the new GMP plasmid manufacturing facility.
Headquartered in Fargo, North Dakota, Aldevron was initially established as a small laboratory in the North Dakota State University in 1998. It later expanded into a biotechnology firm specialising in the production of nucleic acids, proteins, plasmids, RNA, gene editing enzymes and antibodies.
Aldevron provides clients with critical raw materials and key components, which are used for a wide range of research, pre-clinical, clinical, diagnostic and commercial applications, including gene therapy, gene editing and immunotherapy programmes.
The company’s client base spans from some of the largest pharmaceutical companies to small start-ups.
Its Fargo site spans seven acres and includes a 50,000ft² GMP facility.
Taysha Gene Therapies will build a new current Good Manufacturing Practices (cGMP) gene therapy manufacturing facility in Durham, North Carolina,…
Cytiva opened a new facility for manufacturing Xcellerex XDR bioreactors in Shrewsbury, Massachusetts, US, in December 2020. The new manufacturing…
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific is developing a new current good manufacturing practice (cGMP) facility in Carlsbad, California to expand its clinical…